English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Historically, chemotherapy for clear-cell renal cell carcinoma (ccRCC) has not been effective, and fewer than 25% of patients respond to cytokine therapy. Recommended treatment for patients with advanced ccRCC includes molecularly targeted agents such as sunitinib, a kinase inhibitor that targets vascular endothelial growth factor and platelet-derived growth factor receptors. A randomized phase III study established the benefits of sunitinib over interferon alfa, demonstrating an improvement in median progression-free survival (PFS) from 5 to 11 months and a 31% response rate. When a patient progresses on a systemic agent, the typical course of action is to switch therapies. We present a patient with broadly metastatic ccRCC who experienced progression at a single site while receiving sunitinib. After 14 months of sunitinib treatment, stereotactic body radiation therapy (SBRT) to the progressing metastasis allowed the patient to continue on sunitinib for 8 additional months until progression.

Ablation of a Site of Progression With Stereotactic Body Radiation Therapy Extends Sunitinib Treatment From 14 to 22 Months